Evidence map›Paper›PMID 42694981›Full record

ReviewThe Lancet regional health. Western Pacific2026

Liver cancer in Japan: epidemiological transition, viral hepatitis control, and emerging challenges.

Junko Tanaka, Ko Ko, Aya Sugiyama, Chanroth Chhoung, Akemi Kurisu, Masahiro Satake, Tatsuya Kanto, Takaji Wakita, Tomoyuki Akita

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Junko TanakaMedical Policy Office, Hiroshima University, Hiroshima, Japan.
Ko KoGraduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Aya SugiyamaGraduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Chanroth ChhoungGraduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Akemi KurisuGraduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Masahiro SatakeBlood Service Headquarters, Japanese Red Cross, Tokyo, Japan.
Tatsuya KantoJapan Institute for Health Security, Tokyo, Japan.
Takaji WakitaJapan Institute for Health Security, Tokyo, Japan.
Tomoyuki AkitaGraduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Japan has seen a dramatic shift in liver cancer epidemiology, with hepatocellular carcinoma (HCC) declining after decades of comprehensive viral hepatitis control, illustrating the impact of sustained public health intervention. This review examines trends in liver cancer epidemiology in Japan in the context of long-term viral hepatitis control. National data indicate a substantial reduction in disease burden, with liver cancer mortality declining from 34,637 deaths in 2002 to fewer than 30,000 in 2014. The incidence of newly acquired infections is low, with HCV estimated at approximately 0.4 per 100,000 person-years and HBV at 2.38 per 100,000 person-years. These trends likely reflect population-based screening, universal health coverage, and expanded access to antiviral therapy. However, the aetiology of HCC is evolving, with non-viral causes increasing from 6.8% in 1991 to 41.1% in 2015 and accounting for 56.0% of HCC deaths in 2019. Overall, Japan's experience suggests progress in viral hepatitis control, while highlighting the need to address metabolic and lifestyle-related risk factors to sustain future prevention of liver cancer.

Indexed as

ASMRCountermeasuresHBVHCCHCVHealth policyMortality

Identifiers

PMID42694981
PMCPMC13540653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.